Kyowa Kirin company profile
Company profile
Kyowa Kirin has 5,161 employees and is headquartered in Chiyoda, Japan.
Kyowa Kirin sells pharmaceuticals across Japan, the Americas, Europe and Asia, and in other international markets, and its development pipeline spans several therapeutic areas. Its marketed products include Ziftomenib, an oral menin inhibitor for adult relapsed or refractory acute myeloid leukemia with an NPM1 mutation, and Lumicef for palmoplantar pustulosis. Among its late-stage candidates are rocatinlimab for atopic dermatitis and prurigo nodularis, and infigratinib for achondroplasia, both in Phase III trials, alongside programs in ophthalmology, rare metabolic disorders and oncology. The company has research and development partnerships with AstraZeneca and Amgen, and it is a subsidiary of Kirin Holdings Company, Limited.
In the fiscal year ended December 2025, Kyowa Kirin reported revenue of 496.8 billion yen, up 0.3% from the previous year, and net income of 67.0 billion yen. The company employs 5,161 people and is headquartered in Chiyoda, Japan. It was incorporated in 1949 and adopted its current name in July 2019, when it was previously known as Kyowa Hakko Kirin Co., Ltd.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Headquarters
- Otemachi Financial City Grand Cube, 100-0004, Chiyoda
- Employees
- 5,161
- Chief executive
- Abdul Hafeez Mullick
- Founded
- 1949
- Fiscal year
- January - December
- Listing
- 4151 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3256000005
- Website
- kyowakirin.com
Kyowa Kirin and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Kyowa Kirin4151 | Japan | $8.46B | 5,161 | 21.8% | 16.6 |
| Eisai4523 | Japan | $9.14B | 10,543 | 6.7% | 33.3 |
| CiplaCIPLA | India | $11.93B | 31,369 | 13.0% | 38.8 |
| Zhejiang NHU002001 | China | $12.3B | 11,508 | 33.8% | 10.9 |
| Sumitomo Pharma4506 | Japan | $5.69B | 4,980 | -0.4% | 19.2 |
| Zydus LifesciencesZYDUSLIFE | India | $12.59B | 29,980 | 17.2% | 28.4 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
